Actelion appoints coo and extends executive committee

Adapts management to meet the needs of a growing organisation

Actelion has appointed Otto Schwarz as chief operating officer (COO).

Schwarz joined the Swiss biopharmaceutical firm in 2008 as head of business strategy and operations. In addition to commercial operations and business strategy he takes responsibility for corporate services, global quality management and corporate communications, with all three departments retaining their respective heads.

Actelion has also adapted its Executive Committee (AEC), chaired by chief executive Jean-Paul Clozel, to the needs of a growing organisation and to strengthen leadership and governance.

The AEC members include Clozel and Schwarz, plus chief financial officer Andrew Oakley, head of global clinical development Guy Braunstein and chief business development officer Nicholas Franco.

In addition to this core group, the extended AEC includes Christian Albrich (head global human resources), Marian Borovsky (group general counsel), Martine Clozel (chief scientific officer) and Roland Haefeli (head investor relations and public affairs).

In addition, Isaac Kobrin, previously chief medical officer, will take up a new role to plan and ultimately lead a biotech start-up separate from Actelion that will undertake the clinical development of its non-core compounds.

Simon Buckingham, previously head global corporate and business development, will also take up a new role (on a part-time basis) leading special projects and advising on corporate strategic matters.

You may also like

Research & Development

Actelion and the Max Planck Society create Vaxxilon

The new company aims to discover, develop and commercialise synthetic carbohydrate vaccines
Drug Delivery

Major European biopharma company endorses CI Sade weight sorters

Actelion Pharmaceuticals has endorsed CI Precision’s SADE weight sorters for weight checking batches of capsules
Finance

Actelion to cut 40 research jobs in Switzerland

Aims to capitalise on growth in its core area of expertise
Finance

Actelion to cut 135 jobs and refocus r&d effort

Aims to take advantage of expertise in pulmonary arterial hypertension
Research & Development

Actelion to acquire Trophos

Trophos a pipeline of molecular entities in development for motor neuron diseases
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Subscribe now